{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03290950","nct_id":"NCT03290950","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03290950. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.","label":"Cohort 2","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceuticals"],"completion_date":{"date":"2026-09","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":69,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"daratumumab","otherNames":[],"type":"DRUG"},{"name":"carfilzomib","otherNames":[],"type":"DRUG"},{"name":"lenalidomide","otherNames":[],"type":"DRUG"},{"name":"dexamethasone","otherNames":["Cohort 1 administration"],"type":"DRUG"},{"name":"dexamethasone","otherNames":["Cohort 2 administration"],"type":"DRUG"}],"last_update":"2026-05-29","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-05-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Best Overall Response","timeFrame":"Up to 8 cycles"}],"references":[{"citation":"Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9.","pmid":"37945755","type":"DERIVED"}],"start_date":{"date":"2017-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03290950"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03290950"}